FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Limited in Fighting Misinformation: Califf

[ Price : $8.95]

Communications experts tell the Associated Press FDA may have a hard time combating misinformation due to several factors, includi...

Info Collection on BLA Requirements

[ Price : $8.95]

Federal Register notice: FDA sends to OMB an information collection extension entitled Biologics License Applications (BLAs) Proce...

510(k) Certification Information Collection

[ Price : $8.95]

Federal Register notice: FDA revises an information collection entitled Premarket Notification 21 CFR Part 807, Subpart E.

510(k) Guidances for 2 Ultrasound-type Devices Published

[ Price : $8.95]

FDA publishes two 510(k) guidances on ultrasound and related types of devices.

Intarcia Agrees to Advisory Committee to Resolve Review Dispute

[ Price : $8.95]

Intarcia Therapeutics accepts an FDA proposal to allow an advisory committee to review and address a 2021 CDER decision not to app...

Lagevrio Misses Endpoint in Covid-19 Study

[ Price : $8.95]

Merck says a study of its Covid-19 drug Lagevrio (molnupiravir) did not meet the primary endpoint a statistically significant ris...

Regulatory Agenda Eyes DTC Ads and Med Guides

[ Price : $8.95]

HHS publishes its semiannual regulatory agenda that outlines numerous FDA rulemaking activities under development, including a fin...

Pfizer Drops Many U.S. Lyme Trial Participants

[ Price : $8.95]

Pfizer drops about half of the U.S. participants in its VALOR Lyme vaccine Phase 3 trial due to trial site good clinical practice ...

Priority Review for Merck Prevymis sNDA

[ Price : $8.95]

FDA grants priority review for a Merck sNDA to extend the use of its Prevymis to CMV prophylaxis in kidney transplant patients.

FDA to Review Iveric NDA for Avacincaptad Pegol

[ Price : $8.95]

FDA accepts an Iveric Bio NDA for avacincaptad pegol for priority review with a Breakthrough Therapy designation to treat geograph...